Compare Mesoblast Limited (MESO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Open Text Corporation — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Open Text Corporation trades at $23.98 (market cap $5.80B). The key difference: Open Text Corporation is far larger — about 2.6× Mesoblast Limited's market cap, and Open Text Corporation pays a 4.67% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | OTEX | |
|---|---|---|
Market Cap | $2.21B | $5.80B |
Sector | Technology | Technology |
52-Week High | $20.96 | $39.69 |
52-Week Low | $12.88 | $20.01 |
Enterprise Value | $2.21B | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Open Text Corporation (OTEX) trades at $24.94, down 2.81% in the last session, with a bullish technical signal from moving averages and strong support at $24. The company reported Q2 2026 EPS of $1.23, beating estimates, and maintains robust profitability with a 73.74% gross margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe, signaling strategic expansion.
OTEX presents a value opportunity with a low P/E of 9.58 and a consensus price target of $29.33, implying 17.6% upside. Risks include high long-term debt of $6.34 billion and competitive pressures in software. Analyst sentiment is mixed, with 42% buy ratings, but earnings beats and dividend stability support a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
